Tom Mulder

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCERS. 2024;16(22):3821
A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)
Zhong W; Kokhaei P; Mulder TA; Ghaderi A; Moshfegh A; Lundin J; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Journal article: HEMASPHERE. 2023;7(Suppl):e18051e0
P609: EFFECT OF LONG‐TERM ZANUBRUTINIB TREATMENT ON T‐CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB‐3111‐304 AND 305 TRIALS.
Andersson M; Mulder TA; Heimersson K; Sönnert‐Husa S; Giertz A; Hansson L; Karlsson C; Lundin J; Österborg A; Palma M
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:318
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Xagoraris I; Mulder T; Stathopoulou K; Xyderou P; Andersson M; Palma M; Rassidakis G
Article: HEMASPHERE. 2022;6(11):e794
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
Mulder TAA; Andersson MLL; Pena-Perez L; Heimersson K; Xagoraris I; Wahlin BE; Mansson R; Hansson L; Rassidakis G; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl ):15-16
P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
Mulder TA; Andersson ML; Peña-Pérez L; Heimersson K; Xagoraris I; Wahlin BE; Månsson R; Hansson L; Rassidakis GZ; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl ):1168-1169
P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
Mulder TA; Andersson ML; Heimersson K; Xagoraris I; Wahlin BE; Rassidakis G; Hansson L; Palma M
Article: EJHAEM. 2021;2(3):525-529
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: HEMASPHERE. 2021;5(5):e564
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia
Mulder TA; Pena-Perez L; Berglof A; Meinke S; Estupinan HY; Heimersson K; Zain R; Mansson R; Smith CIE; Palma M
Article: ONCOIMMUNOLOGY. 2021;10(1):1935557
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
Van Wigcheren GF; De Haas N; Mulder TA; Horrevorts SK; Bloemendal M; Hins-Debree S; Mao Y; Kiessling R; van Herpen CML; Florez-Grau G; Hato SV; De Vries IJM
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Palma M; Hansson L; Mulder TA; Adamson L; Nasman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Osterborg A; Mellstedt H

Alla övriga publikationer

Thesis / dissertation: 2022
Immune cells in chronic lymphocytic leukemia and Hodgkin lymphoma in relation to tumor burden and treatment
Mulder, Tom Adriaan
Review: FRONTIERS IN IMMUNOLOGY. 2021;12:686768
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Palma M; Mulder TA; Osterborg A
Conference publication: LEUKEMIA & LYMPHOMA. 2020;61:81-84
Effect of long-term ibrutinib treatment on T-cell number and profile in relapsed or refractory chronic lymphocytic leukemia patients: correlation with clinical response and tumor burden up to 4-years follow-up
Palma M; Heimersson K; Mulder T; Mellstedt H; Osterborg A
Conference publication: LEUKEMIA & LYMPHOMA. 2020;61:66-67
Real-world data on the PI3Kd inhibitor idelalisib in relapsed/refractory CLL patients treated in Sweden
Mattsson A; Sylvan S; Mulder T; Axelsson P; Ellin F; Lewerin C; Uggla B; Osterborg A; Hansson L
Conference publication: BLOOD. 2019;134:5445
Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease
Palma M; Mulder TA; Heimersson K; Rathje L-S; Olin T; Schultz J; Mellstedt H; Osterborg A
Review: CANCERS. 2019;11(7):E915-915
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
Mulder TA; Wahlin BE; Osterborg A; Palma M
Meeting abstract: BLOOD. 2018;132:4421
Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatement in Relapsed or Refactory Chronic Lymphocytic Leukemia Patients
Palma M; Heimersson K; Mulder TA; Nasman-Glaser B; Osterborg A; Mellstedt H
Conference publication: LEUKEMIA & LYMPHOMA. 2017;58:38-39
Vaccination with dendritic cells loaded with autologous leukemic cells in combination with low-dose lenalidomide in chronic lymphocytic leukemia (CLL) patients: an early clinical trial
Heimersson K; Mozaffari F; Mulder T; Palma M; Hansson L; Adamson L; Nasman-Glaser B; Svensson A; Gentilcore G; Osterborg A; Mellstedt H

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2022-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2022

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI